Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc.
Your view on AVTX
Overview
What the company does, where it operates, and who runs it.
About Avalo Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Garry A. Neil
- Headquarters
- 540 Gaither Road, Rockville, MD, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Garry A. Neil
- Headquarters
- 540 Gaither Road, Rockville, MD, US
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases.
It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis.
Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG.
The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Avalo Therapeutics, Inc. from FRC's valuation model, read against the market price. AVTX last traded at $7.76; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Avalo Therapeutics, Inc.. Starting points for Avalo Therapeutics, Inc.: EPS -$1.61, beta 0.74 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Avalo Therapeutics, Inc.. Avalo Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Avalo Therapeutics, Inc.. Trailing twelve-month EPS for Avalo Therapeutics, Inc. stands at -$1.61. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$36.56
average of 9 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy5
- Hold2
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.46 | -$0.51 | -$2.50 | -$2.45 |
| Low estimate | -$0.52 | -$0.56 | -$2.79 | -$3.00 |
| High estimate | -$0.35 | -$0.43 | -$2.29 | -$1.56 |
| No. of analysts | 7 | 3 | 8 | 9 |
| Year-ago EPS | -$2.301 | -$0.98 | -$5.84 | — |
| Growth | — | +48.1% | +57.3% | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $1.00M | $1.00M |
| Low estimate | $0.00 | $0.00 | $1.00M | $1.00M |
| High estimate | $0.00 | $0.00 | $1.00M | $1.00M |
| No. of analysts | 0 | 0 | 12 | 12 |
| Year-ago revenue | $192000.00 | $0.00 | $59000.00 | — |
| Growth | -100.0% | — | +1594.9% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 14, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Avalo Therapeutics, Inc.. Avalo Therapeutics, Inc. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ACRSAclaris Therapeutics, Inc.Biotechnology$622M
- AGMBAgomAb Therapeutics N.V. American Depositary SharesBiotechnology$313M
- ANABAnaptysBio, Inc.Biotechnology$1.4B
- ELDNEledon Pharmaceuticals, Inc.Biotechnology$172M
- IFRXInflaRx N.V.Biotechnology$172M
- IMUXImmunic, Inc.Biotechnology$103M
- ODTXOdyssey Therapeutics, Inc.Biotechnology$920M
- QTTBQ32 Bio Inc.Biotechnology$261M
More Biotechnology companies
- PVLAPalvella Therapeutics, Inc.NASDAQ$2.2B
- PXMDPaxMedica, Inc. Common StockOTC$37,879
- PXXLFPoxel S.A.OTC$13M
- PYC.AXPYC Therapeutics LimitedASX
- PYPDPolyPid Ltd.NASDAQ$127M
- PYXSPyxis Oncology, Inc.NASDAQ$100M
- PZRXQPhaseRx, Inc.OTC$1,169
- QNCXQuince Therapeutics, Inc.NASDAQ$9M
- QNRXQuoin Pharmaceuticals, Ltd.NASDAQ$7M
- OCULOcular Therapeutix, Inc.NASDAQ$1.4B
- OGENOragenics, Inc.AMEX$906,903
ETFs holding Avalo Therapeutics, Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.11%
- IWMiShares Russell 2000 ETF$76.6B in assets0.01%
- VXFVanguard Extended Market ETF$30.2B in assets0.01%
- BBCVirtus LifeSci Biotech Clinical Trials ETF$38M in assets0.43%
- IWCiShares Micro-Cap ETF$1.3B in assets0.11%
- VFMOVanguard U.S. Momentum Factor ETF$1.9B in assets0.06%
- BFLXiShares Flexible Equity Active ETF$2.2B in assets0.03%
Largest holders first, then the funds most concentrated in AVTX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Avalo Therapeutics, Inc., and how their positions are changing. At a $448.7M market value, institutional positions materially move Avalo Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Avalo Therapeutics, Inc. executives and directors. Shares of Avalo Therapeutics, Inc. have traded between $3.39 and $19.41 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Avalo Therapeutics, Inc.. Coverage tracks Avalo Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Avalo Therapeutics, Inc.